IDEAS home Printed from https://ideas.repec.org/a/sae/medema/v20y2000i4p451-458.html
   My bibliography  Save this article

A Comprehensive League Table of Cost-Utility Ratios and a Sub-table of "Panel-worthy" Studies

Author

Listed:
  • Richard H. Chapman

    (Address correspondence and reprint requests to Dr. Neumann. Harvard Center for Risk Analysis, 718 Huntington Avenue, Boston, MA 02115, telephone (617) 432-1312; fax. (617) 432-0190; e-mail. (pneumann@hsph.harvard edu))

  • Patricia W. Stone

    (Address correspondence and reprint requests to Dr. Neumann. Harvard Center for Risk Analysis, 718 Huntington Avenue, Boston, MA 02115, telephone (617) 432-1312; fax. (617) 432-0190; e-mail. (pneumann@hsph.harvard edu))

  • Eileen A. Sandberg

    (Address correspondence and reprint requests to Dr. Neumann. Harvard Center for Risk Analysis, 718 Huntington Avenue, Boston, MA 02115, telephone (617) 432-1312; fax. (617) 432-0190; e-mail. (pneumann@hsph.harvard edu))

  • Chaim Bell

    (Address correspondence and reprint requests to Dr. Neumann. Harvard Center for Risk Analysis, 718 Huntington Avenue, Boston, MA 02115, telephone (617) 432-1312; fax. (617) 432-0190; e-mail. (pneumann@hsph.harvard edu))

  • Peter J. Neumann

    (Address correspondence and reprint requests to Dr. Neumann. Harvard Center for Risk Analysis, 718 Huntington Avenue, Boston, MA 02115, telephone (617) 432-1312; fax. (617) 432-0190; e-mail. (pneumann@hsph.harvard edu))

Abstract

Objectives. The authors compiled a comprehensive league table of cost/QALY ratios, and a standardized table of analyses satisfying selected Reference Case criteria from the USPHS Panel on Cost-Effectiveness in Health and Medicine. Methods. They identified 228 cost-utility analyses (CUAs) through literature searches, and abstracted data on methods and cost-utility ratios. The subset of "Panel-worthy" analyses used: a societal or broad health-care perspective, community or patient preference weights, net costs, incremental comparisons, and discounting of costs and QALYs. Results. The 228 CUAs included ratios for 647 interventions, ranging from cost-saving to $52,000,000/QALY (median = $12,000/QALY). The standardized table presents 112 ratios that met the "Panel-worthy" criteria, with articles published in recent years more likely to meet all of the criteria. Conclusions. The comprehensive league table (available on the Web) provides a useful reference, but ratios may not be comparable because of methodologic variations. The standardized table focuses on studies meeting basic methodologic criteria, potentially allowing for better comparison with future Reference Case analyses. Future studies should investigate the quality of analyses' underlying assumptions in addition to whether certain key procedural protocols were met. Key words: cost-utility analysis; league tables; economic evaluation. (Med Decis Making 2000;20:451-467)

Suggested Citation

  • Richard H. Chapman & Patricia W. Stone & Eileen A. Sandberg & Chaim Bell & Peter J. Neumann, 2000. "A Comprehensive League Table of Cost-Utility Ratios and a Sub-table of "Panel-worthy" Studies," Medical Decision Making, , vol. 20(4), pages 451-458, October.
    • Handle: RePEc:sae:medema:v:20:y:2000:i:4:p:451-458
    DOI: 10.1177/0272989X0002000409
    as

    Download full text from publisher

    File URL: https://journals.sagepub.com/doi/10.1177/0272989X0002000409
    Download Restriction: no
    File URL: https://libkey.io/10.1177/0272989X0002000409?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. DE GRAEVE, Diana & NONNEMAN, Walter, 1994. "Pharmacoeconomic studies: Pitfalls and problems," SESO Working Papers 1994018, University of Antwerp, Faculty of Business and Economics.
    2. Drummond, Michael & Torrance, George & Mason, James, 1993. "Cost-effectiveness league tables: More harm than good?," Social Science & Medicine, Elsevier, vol. 37(1), pages 33-40, July.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. José M. Labeaga & Xisco Oliver & Amedeo Spadaro, "undated". "Measuring Changes in Health Capital," Working Papers 2005-15, FEDEA.
    2. Georg Meyer & Gediminas Adomavicius & Paul E. Johnson & Mohamed Elidrisi & William A. Rush & JoAnn M. Sperl-Hillen & Patrick J. O'Connor, 2014. "A Machine Learning Approach to Improving Dynamic Decision Making," Information Systems Research, INFORMS, vol. 25(2), pages 239-263, June.
    3. Afschin Gandjour, 2015. "A model to optimize investments in health technologies, quality of care and research," Applied Economics, Taylor & Francis Journals, vol. 47(20), pages 2031-2039, April.
    4. Leonie Segal & Kim Dalziel & Duncan Mortimer, 2010. "Fixing the game: are between‐silo differences in funding arrangements handicapping some interventions and giving others a head‐start?," Health Economics, John Wiley & Sons, Ltd., vol. 19(4), pages 449-465, April.
    5. Richard H. Chapman & Marc Berger & Milton C. Weinstein & Jane C. Weeks & Sue Goldie & Peter J. Neumann, 2004. "When does quality‐adjusting life‐years matter in cost‐effectiveness analysis?," Health Economics, John Wiley & Sons, Ltd., vol. 13(5), pages 429-436, May.
    6. Milton C. Weinstein, 2005. "Spending Health Care Dollars Wisely: Can Cost-Effectiveness Analysis Help? 16th Annual Herbert Lourie Memorial Lecture on Health Policy," Center for Policy Research Policy Briefs 30, Center for Policy Research, Maxwell School, Syracuse University.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Tappenden, P & Brazier, J & Ratcliffe, J, 2006. "Does the National Institute for Health and Clinical Excellence take account of factors such as uncertainty and equity as well as incremental cost-effectiveness in commissioning health care services? A," MPRA Paper 29772, University Library of Munich, Germany.
    2. Rutten, Frans, 1996. "Economic evaluation and health care decision-making," Health Policy, Elsevier, vol. 36(3), pages 215-229, June.
    3. Coast, Joanna, 2018. "A history that goes hand in hand: Reflections on the development of health economics and the role played by Social Science & Medicine, 1967–2017," Social Science & Medicine, Elsevier, vol. 196(C), pages 227-232.
    4. Wolfgang C. Winkelmayer & Milton C. Weinstein & Murray A. Mittleman & Robert J. Glynn & Joseph S. Pliskin, 2002. "Health Economic Evaluations: The Special Case of End-Stage Renal Disease Treatment," Medical Decision Making, , vol. 22(5), pages 417-430, October.
    5. Cookson, Richard & Hutton, John, 2003. "Regulating the economic evaluation of pharmaceuticals and medical devices: a European perspective," Health Policy, Elsevier, vol. 63(2), pages 167-178, February.
    6. Tom Jefferson & Miranda Mugford & Alastair Gray & Vittorio Demicheli, 1996. "An exercise on the feasibility of carrying out secondary economic analyses," Health Economics, John Wiley & Sons, Ltd., vol. 5(2), pages 155-165, March.
    7. Lindholm, Lars & Rosen, Mans & Emmelin, Maria, 1996. "An epidemiological approach towards measuring the trade-off between equity and efficiency in health policy," Health Policy, Elsevier, vol. 35(3), pages 205-216, March.
    8. Joakim Ramsberg, 2002. "When should expenditure per life saved vary?," Journal of Risk Research, Taylor & Francis Journals, vol. 5(3), pages 249-263, July.
    9. Raymond C.W. Hutubessy & Rob M.P.M. Baltussen & David B. Evans & Jan J. Barendregt & Christopher J.L. Murray, 2001. "Stochastic league tables: communicating cost‐effectiveness results to decision‐makers," Health Economics, John Wiley & Sons, Ltd., vol. 10(5), pages 473-477, July.
    10. Gafni, Amiram & Birch, Stephen, 2006. "Incremental cost-effectiveness ratios (ICERs): The silence of the lambda," Social Science & Medicine, Elsevier, vol. 62(9), pages 2091-2100, May.
    11. Christopher J.L. Murray & David B. Evans & Arnab Acharya & Rob M.P.M. Baltussen, 2000. "Development of WHO guidelines on generalized cost‐effectiveness analysis," Health Economics, John Wiley & Sons, Ltd., vol. 9(3), pages 235-251, April.
    12. Drummond, Michael & Mason, James & Torrance, George, 1995. "Cost-effectiveness league tables: think of the fans," Health Policy, Elsevier, vol. 31(3), pages 231-238, March.
    13. Debby Postulart & Eddy M.M. Adang, 2000. "Response Shift and Adaptation in Chronically III Patients," Medical Decision Making, , vol. 20(2), pages 186-193, April.
    14. James Mason & Mike Drummond, 1995. "The DH register of cost-effectiveness studies: a review of study content and quality," Working Papers 128chedp, Centre for Health Economics, University of York.
    15. Samuel Shillcutt & Damian Walker & Catherine Goodman & Anne Mills, 2009. "Cost Effectiveness in Low- and Middle-Income Countries," PharmacoEconomics, Springer, vol. 27(11), pages 903-917, November.
    16. Andrew R. Willan & Bernie J. O'Brien, 1996. "Confidence intervals for cost‐effectiveness ratios: An application of Fieller's theorem," Health Economics, John Wiley & Sons, Ltd., vol. 5(4), pages 297-305, July.
    17. A. David Paltiel & Julie A. Scharfstein & George R. Seage & Elena Losina & Sue J. Goldie & Milton C. Weinstein & Donald E. Craven & Kenneth A. Freedberg, 1998. "A Monte Carlo Simulation of Advanced HIV Disease," Medical Decision Making, , vol. 18(2_suppl), pages 93-105, April.
    18. Phusit Prakongsai & Natasha Palmer & Preecha Uay-Trakul & Viroj Tangcharoensathien & Anne Mills, 2009. "The implications of benefit package design: the impact on poor Thai households of excluding renal replacement therapy," Journal of International Development, John Wiley & Sons, Ltd., vol. 21(2), pages 291-308.
    19. Peter J. Neumann & Darren E. Zinner & Janice C. Wright, 1997. "Are Methods for Estimating QALYs in Cost-Effectiveness Analyses Improving?," Medical Decision Making, , vol. 17(4), pages 402-408, October.
    20. Ann E. Clarke, 1997. "Arthritis Patient Education: How Economic Evaluations Can Inform Health Policy," Canadian Public Policy, University of Toronto Press, vol. 23(s1), pages 162-176, Spring.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:sae:medema:v:20:y:2000:i:4:p:451-458. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: SAGE Publications (email available below). General contact details of provider: .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.